- 7/24 Live Call Center
Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Immunotherapy, also known as biologic therapy or biotherapy, is a major change in how cancer is treated. Instead of attacking the tumor directly, it works by helping the body’s own immune system find and destroy cancer cells. Chemotherapy kills fast-growing cells, and radiation damages DNA, but immunotherapy is different. It is based on the idea that cancer develops when the immune system fails to spot and remove abnormal cells. By restoring this ability, immunotherapy can sometimes control or even cure the disease for a long time.
In the contemporary medical landscape, immunotherapy is not a monolith but a diverse arsenal of therapeutic modalities. It encompasses Immune Checkpoint Inhibitors, which release the “brakes” on T-cells; Adoptive Cell Therapies (like CAR-T), which involve the genetic engineering of living immune cells; Cancer Vaccines, which train the immune system to recognize tumor-specific antigens; and Monoclonal Antibodies, which can flag cancer cells for destruction or block vital survival signals. This multifaceted approach defines immunotherapy as a systemic, adaptive, and often “living” treatment that can evolve alongside the tumor, offering the potential for long-term immunological memory and protection against recurrence.
Immunotherapy uses the body’s natural ability to heal and protect itself. The immune system is built to tell the difference between normal cells and foreign or damaged ones. Cancer cells can change to hide from the immune system, making them hard to detect. Immunotherapy helps the immune system find and attack these hidden cancer cells. Instead of using drugs to poison cancer, this approach strengthens the body’s own defenses to fight the disease.
The foundation of immunotherapy lies in the concept of cancer immune surveillance. In a healthy organism, the immune system constantly patrols tissues, identifying and eliminating cells that have undergone malignant transformation. This is mediated by cytotoxic T-lymphocytes (CTLs) and Natural Killer (NK) cells. However, tumors develop through a process known as the “Three Es”: Elimination, Equilibrium, and Escape.
Immunotherapy targets the “Escape” phase. Tumors escape by expressing checkpoint proteins (such as PD-L1) that bind to T cells and deactivate them, or by recruiting immunosuppressive cells (such as Regulatory T cells) into the tumor microenvironment. Understanding these escape mechanisms is the definition of modern immuno-oncology diagnostics.
mmunotherapy is advancing quickly around the world. Instead of using the same treatment for everyone, doctors can now personalize care using special tests called biomarkers, like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), to see who will benefit most. New treatments, such as ready-made cell therapies, are being developed to make options like CAR-T more widely available. Making these advanced therapies accessible to more people is a major goal in cancer care today.
A key benefit of immunotherapy is that it can help rebuild the immune system. While chemotherapy often weakens immunity, immunotherapy works to strengthen it. These treatments help the immune system remember the cancer, much like a vaccine helps the body remember a virus. This means some patients can stay cancer-free for years after treatment ends, which is now seen as a major sign of success.
Key Physiological Mechanisms Utilized
Stroma Remodeling: Some immunotherapies target the tumor stroma (connective tissue) to facilitate immune cell infiltration into the tumor core.
Send us all your questions or requests, and our expert team will assist you.
Active immunotherapy stimulates the patient’s immune system to work harder or smarter to attack cancer cells (e.g., vaccines and checkpoint inhibitors). Passive immunotherapy involves giving the patient immune system components (such as artificial antibody proteins) created outside the body to directly attack the cancer, without necessarily relying on the patient’s immune response to initiate the attack.
For some patients with advanced cancers (like melanoma or lung cancer), immunotherapy has led to complete remission that lasts for years, which many doctors consider a functional cure. However, it does not work for everyone. For many others, it turns cancer into a manageable chronic condition. The goal is to achieve a “durable response” in which the tumor remains controlled without growing.
Traditional vaccines (like the flu vaccine) are preventive; they are given to healthy people to prevent infection. Cancer vaccines (a type of immunotherapy) are usually therapeutic; they are given to people who already have cancer to teach their immune system to recognize and attack the specific cancer cells they have. Preventative cancer vaccines (like HPV) do exist, but therapeutic ones are the focus of treatment.
Unlike chemotherapy, which attacks all rapidly dividing cells, immunotherapy is more targeted. However, because it unleashes the immune system, it can sometimes cause it to attack healthy organs (autoimmunity), leading to side effects such as inflammation of the lungs, colon, or skin. These are “immune-related adverse events.”
Checkpoints are proteins on immune cells that act like switches to turn the immune response on or off. Their natural job is to prevent the immune system from being too aggressive and attacking healthy body cells. Cancer cells often hijack these checkpoints (turning them “off”) to hide from the immune system. Immunotherapy drugs called “checkpoint inhibitors” block this interaction, flipping the switch back “on.”
Immunotherapy vs chemotherapy: Chemo kills fast-growing cells, while immunotherapy boosts the immune system to target cancer more precisely. Chemotherapy has long been a key part
A groundbreaking clinical trial has shown a 100% success rate with a new cancer drug. This drug is effective in treating a specific type of
Your Comparison List (you must select at least 2 packages)
